The Efficacy of Dexketoprofen for Migraine Attack: A Meta-analysis of Randomized Controlled Studies

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Nov 15

PMID 31725614

Citations 3

Authors

Baohua Yang

Zhili Xu

Linglong Chen

Xinguo Chen

Yuequn Xie

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy of dexketoprofen for migraine attack remains controversial. We conduct a systematic review and meta-analysis to explore the influence of dexketoprofen supplementation versus placebo on pain control in migraine attack patients.

Methods: We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2019 for randomized controlled trials (RCTs) assessing the effect of dexketoprofen supplementation versus placebo on pain control for migraine attack patients. This meta-analysis is performed using the random-effect model.

Results: Five RCTs involving 794 patients are included in the meta-analysis. Overall, compared with control group for migraine attack, dexketoprofen supplementation is associated with substantially increased pain free at 2 hours (RR = 1.90; 95% CI = 1.43-2.53; P < .0001), pain free at 48 hours (RR = 1.63; 95% CI = 1.07-2.49; P = .02), good or excellent treatment (RR = 1.48; 95% CI = 1.24-1.78; P < .0001) and pain relief at 2 hours (RR = 1.80; 95% CI = 1.17-2.77; P = .007), as well as reduced need for rescue drug (RR = 0.64; 95% CI = 0.43-0.94; P = .02), with no significant increase in adverse events (RR = 1.51; 95% CI = 0.87-2.62; P = .14).

Conclusion: Dexketoprofen supplementation benefits to improve pain control at 48 hours and reduce the need for rescue drug in migraine attack patients.

Citing Articles

Non-opioid Intravenous Drugs for Pain Management in Patients Presenting with Acute Migraine Pain in the Emergency Department: A Comprehensive Literature Review.

Zarei M, Hajipoor Kashgsaray N, Asheghi M, Shahabifard H, Soleimanpour H Anesth Pain Med. 2023; 12(5):e132904.

PMID: 36937180 PMC: 10016134. DOI: 10.5812/aapm-132904.

Intradermal mesotherapy versus intravenous dexketoprofen for the treatment of migraine headache without aura: a randomized controlled trial.

Akbas I, Kocak M, Kocak A, Akgol Gur S, Dogruyol S, Demir M Ann Saudi Med. 2021; 41(3):127-134.

PMID: 34085549 PMC: 8176379. DOI: 10.5144/0256-4947.2021.127.

Emergency Department and Inpatient Management of Headache in Adults.

Robblee J, Grimsrud K Curr Neurol Neurosci Rep. 2020; 20(4):7.

PMID: 32189074 DOI: 10.1007/s11910-020-01030-w.

References

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari M, Zava D . A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain. 2010; 12(2):219-26. PMC: 3075392. DOI: 10.1007/s10194-010-0243-y. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

Allais G, De Lorenzo C, Airola G, Peano S, Benedetto C . [Dexketoprofen trometamol in the treatment of acute migraine attack]. Minerva Med. 2001; 91(7-8):153-9. View

Vinson D . Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002; 39(3):215-22. DOI: 10.1067/mem.2002.121400. View

Etchison A, Bos L, Ray M, McAllister K, Mohammed M, Park B . Low-dose Ketamine Does Not Improve Migraine in the Emergency Department: A Randomized Placebo-controlled Trial. West J Emerg Med. 2018; 19(6):952-960. PMC: 6225951. DOI: 10.5811/westjem.2018.8.37875. View

Gungor F, Akyol K, Kesapli M, Celik A, Karaca A, Bozdemir M . Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial. Cephalalgia. 2015; 36(2):179-84. DOI: 10.1177/0333102415584604. View

Derry S, Rabbie R, Moore R . Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013; (4):CD008783. PMC: 6483674. DOI: 10.1002/14651858.CD008783.pub3. View

Cortelli P, Allais G, Tullo V, Benedetto C, Zava D, Omboni S . Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci. 2011; 32 Suppl 1:S95-8. DOI: 10.1007/s10072-011-0551-2. View

10.

Kacperski J, Hershey A . Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine. CNS Drugs. 2016; 30(9):837-44. DOI: 10.1007/s40263-016-0375-y. View

11.

Caldwell J, Hutt A, Fournel-Gigleux S . The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol. 1988; 37(1):105-14. DOI: 10.1016/0006-2952(88)90762-9. View

12.

MacGregor E . Migraine. Ann Intern Med. 2017; 166(7):ITC49-ITC64. DOI: 10.7326/AITC201704040. View

13.

Evers S, Afra J, Frese A, Goadsby P, Linde M, May A . EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009; 16(9):968-81. DOI: 10.1111/j.1468-1331.2009.02748.x. View

14.

Golikhatir I, Cheraghmakani H, Bozorgi F, Jahanian F, Sazgar M, Montazer S . The Efficacy and Safety of Prochlorperazine in Patients With Acute Migraine: A Systematic Review and Meta-Analysis. Headache. 2019; 59(5):682-700. DOI: 10.1111/head.13527. View

15.

Allais G, Bussone G, Tullo V, Cortelli P, Valguarnera F, Barbanti P . Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial. Cephalalgia. 2014; 35(1):45-50. PMC: 4261077. DOI: 10.1177/0333102414542290. View

16.

Maasumi K, Tepper S, Kriegler J . Menstrual Migraine and Treatment Options: Review. Headache. 2016; 57(2):194-208. DOI: 10.1111/head.12978. View

17.

Allais G, Tullo V, Cortelli P, Barbanti P, Valguarnera F, Sette G . Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura. Neurol Sci. 2014; 35 Suppl 1:107-13. PMC: 4035546. DOI: 10.1007/s10072-014-1751-3. View

18.

Mainardi F, Maggioni F, Pezzola D, Zava D, Zanchin G . Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study. J Pain. 2014; 15(4):388-94. DOI: 10.1016/j.jpain.2013.12.006. View

19.

Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, DAmico D, Diener H . Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012; 32(1):6-38. DOI: 10.1177/0333102411417901. View

20.

Tepper S, Diener H, Ashina M, Brandes J, Friedman D, Reuter U . Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019; 92(20):e2309-e2320. PMC: 6598821. DOI: 10.1212/WNL.0000000000007497. View